Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

10,957 total articles

DocuSign: Margin Repairs and Buybacks Create a Tactical Buy

DocuSign: Margin Repairs and Buybacks Create a Tactical Buy

DocuSign's recent beat-and-raise, rising free cash flow and aggressive buybacks make it a constructive mid-term trade. At a $8.6B market cap and FCF of $1.12B, the company is generating cash at a rate that supports buybacks and margin expansion. We recommend a tactical long with a $45.18 entry, $55 target and $40 stop, horizon ~45 trading days, wit…

Herc (HRI): Buying the Post‑Acquisition Growth Story — Data Center Exposure and Scale Make This a Conviction Trade

Herc (HRI): Buying the Post‑Acquisition Growth Story — Data Center Exposure and Scale Make This a Conviction Trade

Herc Holdings (HRI) looks positioned to leverage scale from the H&E acquisition and growing demand in power and rental markets to expand margins and capture share. The stock trades at a reasonable ev/ebitda of 7.1 and a market cap of roughly $5.05B, offering an asymmetric risk/reward for a disciplined long trade: entry $152.00, target $175.00, stop…

Buy the GDX Inclusion Dip: Aya Gold & Silver — Mid-Term Trade Idea

Buy the GDX Inclusion Dip: Aya Gold & Silver — Mid-Term Trade Idea

Aya Gold & Silver's recent pullback looks like a tactical buying opportunity. Inclusion in the VanEck Gold Miners ETF (GDX) and continued operational progress at Zgounder and Boumadine support higher liquidity and a re-rating. This trade sets a clear entry at $19.00, a stop at $17.00 and a target at $25.00 for a mid-term hold (45 trading days).

Buy REGENXBIO Now: FDA Reversal Could Re-Price the Gene-Therapy Story

Buy REGENXBIO Now: FDA Reversal Could Re-Price the Gene-Therapy Story

REGENXBIO (RGNX) offers asymmetric upside if the FDA reversal on NAVSUNLI is confirmed and the company moves toward an accelerated approval (AA) filing for a DMD program. At roughly $543M market cap and $10.50 per share, the risk/reward favors a long entry near current prices with a stop below the $8 area and a near-term target around prior highs.

Why Eli Lilly Ran Up 7% and How to Trade the Momentum

Why Eli Lilly Ran Up 7% and How to Trade the Momentum

Eli Lilly jumped about 7% on heavy volume after a string of favorable regulatory and access developments - an EMA positive opinion for Jaypirca and Medicare coverage for its GLP-1 obesity drugs starting 07/01/2026. The move looks tradeable, but the shares are richly valued and technically extended. I lay out a concrete swing trade with entry, stop …

Why Berkshire Could Be Your Best Defense If Markets Crack

Why Berkshire Could Be Your Best Defense If Markets Crack

Berkshire Hathaway sits on an unprecedented cash pile, trades at reasonable multiples for its quality assets, and combines insurance float, regulated utilities and a railroad that all perform in recessions. This trade plan aims to own BRK.A around current levels as a defensive, opportunity-exposure trade: entry $746,597.92, stop $710,000.00, target…

Why Marvell’s Jensen-Fueled Pop Looks Like a Trade, Not a Trap

Why Marvell’s Jensen-Fueled Pop Looks Like a Trade, Not a Trap

Marvell surged on optimism around custom AI silicon and optics after high‑profile bullish comments and reported guidance upside. The fundamentals support a tactical long: strong revenue momentum, healthy margins, and manageable leverage. Valuation is rich, so this is a controlled swing trade with a tight stop and a clear exit plan.

Buying the Dip in Petrobras: Add Size on Oversold Levels

Buying the Dip in Petrobras: Add Size on Oversold Levels

Petrobras (PBR) checks the boxes for a tactical, long-term accumulation: cheap valuation (P/E 5.3, PB 1.23), a 6.3% yield, strong free cash flow profile in an environment of stable oil prices, and fresh service agreements that underpin production continuity. Technicals show oversold momentum (RSI ~26.7) after a recent pullback; we propose an entry …

Buy the AI Optionality: Qualcomm as a Free Call on Data Center AI

Buy the AI Optionality: Qualcomm as a Free Call on Data Center AI

<p>Qualcomm's sudden pivot to data center AI — anchored by its Dragonfly C1000 CPU and a multi-year deal with Meta — materially re-rates the firm's growth runway without forcing investors to pay top-dollar for the story. The stock pulled back sharply into a technical and sentiment reset, creating a tactical long opportunity with defined risk. This …

Bloom Energy: The Drop Was Mechanical — Buy the Data-Center Rebound

Bloom Energy: The Drop Was Mechanical — Buy the Data-Center Rebound

Bloom Energy (BE) sold off sharply after a blistering run to new highs. Fundamentals remain intact: large AI data-center contracts, upgraded 2026 revenue guidance and positive free cash flow. The plunge appears driven by heavy volume and rotation rather than fresh negative business news. Trade plan: enter $260.00, stop $220.00, target $340.00 over …

EZCORP: Cheap Valuation Backing Rapid Store-Led Growth

EZCORP: Cheap Valuation Backing Rapid Store-Led Growth

Ezcorp is growing through acquisitions and store openings while still trading at single-digit EV/EBITDA and mid-teens P/E. With record revenue growth, expanding store count and a conservative balance sheet, the risk/reward favors a long trade sized for volatility. Entry $32.50, target $37.00, stop $29.00, horizon 180 trading days.

Buy the Dip: Salesforce Looks Cheap With Real Cash Flow and AI Tailwinds

Buy the Dip: Salesforce Looks Cheap With Real Cash Flow and AI Tailwinds

Salesforce is trading at a multi-year valuation discount while still growing mid-teens and generating meaningful free cash flow. With AI product rollouts, a strategic stake in Anthropic and the recent Fin acquisition, the company has catalysts that could re-rate the stock. This trade recommends a long entry at current levels with a tight stop and a…

Qualcomm: Buy the M&A-Fueled Dip — Catalyst-Driven Rebound Trade

Qualcomm: Buy the M&A-Fueled Dip — Catalyst-Driven Rebound Trade

Qualcomm's pivot beyond handsets — driven by M&A, new AI silicon (Dragonfly C1000) and an ambitious $40B non-handset target — changes the growth narrative. After a sharp intraday gap lower, the stock offers a disciplined dip-buy entry with defined stop and a realistic upside target backed by cash flow, licensing moat and improving data-center tract…

Albemarle: Buying the 'Other' Storage Boom on a Deep Pullback

Albemarle: Buying the 'Other' Storage Boom on a Deep Pullback

Albemarle (ALB) is oversold after a sharp pullback. The company sits squarely in the secular storage thematic that goes beyond EVs - grid-scale storage, industrial batteries, and specialty lithium chemicals. Balance-sheet strength, positive free cash flow ($577M), and a manageable EV of ~$16.56B create a risk-reward setup. This trade targets $200 w…